Posted: 06/23/2025 03:18 am
PROCEPT BioRobotics Corporation, a key player in the surgical and medical instruments sector, continues to position itself as an innovative force, particularly in the field of urology. This strategic direction is mirrored in both their recent corporate actions and executive compensation structures.
The compensation for PROCEPT BioRobotics' top executives reflects the company's robust commitment to attracting and retaining talent capable of driving its mission forward. Reza Zadno, Ph.D., the President and Chief Executive Officer, earned a total compensation of $6,521,876 in 2024, a significant increase from his $1,374,745 earnings in 2021. This figure includes a base salary of $671,900, with no cash bonus awarded, but substantial stock and option awards amounting to $4,069,082 and $1,141,244, respectively. Additionally, his incentive plan compensation amounted to $639,650, underlining a strong link between compensation and performance^1^.
In comparison, Kevin Waters, the Executive Vice President and Chief Financial Officer, had a total compensation of $1,322,305 in 2022. His earnings included a base salary of $415,000, with the bulk of his compensation coming from stock and option awards worth $276,911 and $301,294, alongside incentive plan compensation of $329,100. Similarly, Alaleh Nouri, the Chief Legal Officer, received a total compensation of $962,247 in the same year, structured with a base salary of $398,000, supplemented by stock awards, option awards, and performance incentives^2^.
These compensation packages underscore PROCEPT BioRobotics' strategy of leveraging equity to align the interests of its executives with those of its shareholders. This is particularly relevant given the current stock price of $60.22, which has experienced fluctuations within a year-high of $103.81 and a low of $47.04^3^. The use of stock awards and options encourages long-term value creation, aligning with the company's goals to drive innovations such as their Aquablation Therapy, which has shown promising results in clinical trials^4^.
Recent corporate developments also highlight the company's ongoing efforts to engage investors and the medical community. PROCEPT BioRobotics is actively involved in scientific presentations and investor conferences, underscoring their commitment to transparency and stakeholder engagement^5^. These activities not only bolster their market position but also have potential implications for future financial performance and executive compensation.
In conclusion, PROCEPT BioRobotics Corporation’s executive compensation strategy is reflective of its broader corporate ambitions, emphasizing performance-based rewards and stakeholder alignment, a critical consideration as the company continues to innovate in surgical robotics.
1. Reza Zadno's 2024 compensation details from SEC filing: [SEC.gov](https://www.sec.gov/Archives/edgar/data/1588978/000158897825000028/0001588978-25-000028-index.htm).
2. Kevin Waters and Alaleh Nouri's 2022 compensation details: [SEC.gov](https://www.sec.gov/Archives/edgar/data/1588978/000162828024017167/0001628280-24-017167-index.htm) and [SEC.gov](https://www.sec.gov/Archives/edgar/data/1588978/000162828023013251/0001628280-23-013251-index.htm).
3. Current stock price data from market overview.
4. Clinical trial results discussion: [GlobeNewswire](https://www.globenewswire.com/news-release/2025/03/24/3047778/0/en/WATER-III-Randomized-Controlled-Trial-Results-Announced-at-European-Association-of-Urology-Comparing-Aquablation-Therapy-to-Laser-Enucleation.html).
5. Corporate event and investor presentation details: [GlobeNewswire](https://www.globenewswire.com/news-release/2025/04/29/3070756/0/en/PROCEPT-BioRobotics-to-Attend-Four-Upcoming-Investor-Conferences-in-May-June.html).
